ACAD
39.28
+0.06
+0.15%
AEMD
3.776
+0.016
+0.4309%
APRI
3.206
+0.316
+10.9446%
ARNA
1.49
0.00
0.00%
ATEC
2.91
+0.02
+0.69%
CNAT
5.25
+0.03
+0.57%
CRXM
0.255
+0.033
+14.968%
CYTX
1.85
-0.04
-2.12%
DXCM
81.89
+0.5
+0.61%
GNMK
10.545
+0.045
+0.429%
HALO
12.61
+0.05
+0.40%
ILMN
163.37
+2.07
+1.28%
INNV
0.17
+0.01
+6.92%
INO
6.96
-0.04
-0.57%
ISCO
1.04
-0.04
-3.70%
ISIS
57.56
0.00
0.00%
LGND
105.71
+0.38
+0.36%
LPTN
2.93
0.00
0.00%
MBVX
3.01
+0.44
+17.12%
MEIP
1.74
+0.02
+1.16%
MNOV
6.11
+0.03
+0.49%
MRTX
6.2
+0.2
+3.33%
MSTX
0.13
+0.001
+0.6966%
NBIX
44.05
+0.9
+2.09%
NUVA
74.22
+0.25
+0.34%
ONCS
1.4
+0.02
+1.45%
ONVO
2.97
+0.08
+2.77%
OREX
4.38
-0.3
-6.41%
OTIC
15.55
+0.5
+3.32%
QDEL
20.89
+0.2
+0.97%
RCPT
231.96
0.00
0.00%
RGLS
1.15
-0.05
-4.17%
RMD
72.27
+0.35
+0.49%
SCIE
0.001
+0.00
+32.00000%
SPHS
2.76
-0.03
-1.08%
SRNE
5.55
-0.07
-1.33%
TROV
2.1
+0.05
+2.44%
VICL
2.26
-0.01
-0.44%
VOLC
18
0.00
0.00%
ZGNX
10.2
-0.25
-2.39%
ACAD
39.28
+0.06
+0.15%
AEMD
3.776
+0.016
+0.4309%
APRI
3.206
+0.316
+10.9446%
ARNA
1.49
0.00
0.00%
ATEC
2.91
+0.02
+0.69%
CNAT
5.25
+0.03
+0.57%
CRXM
0.255
+0.033
+14.968%
CYTX
1.85
-0.04
-2.12%
DXCM
81.89
+0.5
+0.61%
GNMK
10.545
+0.045
+0.429%
HALO
12.61
+0.05
+0.40%
ILMN
163.37
+2.07
+1.28%
INNV
0.17
+0.01
+6.92%
INO
6.96
-0.04
-0.57%
ISCO
1.04
-0.04
-3.70%
ISIS
57.56
0.00
0.00%
LGND
105.71
+0.38
+0.36%
LPTN
2.93
0.00
0.00%
MBVX
3.01
+0.44
+17.12%
MEIP
1.74
+0.02
+1.16%
MNOV
6.11
+0.03
+0.49%
MRTX
6.2
+0.2
+3.33%
MSTX
0.13
+0.001
+0.6966%
NBIX
44.05
+0.9
+2.09%
NUVA
74.22
+0.25
+0.34%
ONCS
1.4
+0.02
+1.45%
ONVO
2.97
+0.08
+2.77%
OREX
4.38
-0.3
-6.41%
OTIC
15.55
+0.5
+3.32%
QDEL
20.89
+0.2
+0.97%
RCPT
231.96
0.00
0.00%
RGLS
1.15
-0.05
-4.17%
RMD
72.27
+0.35
+0.49%
SCIE
0.001
+0.00
+32.00000%
SPHS
2.76
-0.03
-1.08%
SRNE
5.55
-0.07
-1.33%
TROV
2.1
+0.05
+2.44%
VICL
2.26
-0.01
-0.44%
VOLC
18
0.00
0.00%
ZGNX
10.2
-0.25
-2.39%
Home » Archive by Category

Syndication

On Call Administrative Assistant – Suna Solutions Inc. – San Diego, CA

February 13, 2017 – 1:37 pm

We have an immediate need for an administrative professional to work in a fast-paced, cutting edge biotech facility in the Torrey Pines area…. $15 an hourFrom Indeed – Mon, 13 Feb 2017 21:37:03 GMT – View all San Diego jobs

Mirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference

February 13, 2017 – 1:05 pm

SAN DIEGO, Feb. 13, 2017 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D, Ph.D., President and CEO of Mirati, will provide a corporate overview during a fireside chat presentation at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, March 16, 2017 at 11:30 a.m. ET (8:30am PT) in New York City.

An audio webcast of the presentation will be accessible on the “Investors” page of Mirati’s corporate website at www.mirati.com. A replay of the presentation will be available at the same location for 60 days following the conference.

About Mirati Therapeutics
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of targeted oncology products intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs. Our clinical pipeline consists of three product candidates: glesatinib, sitravatinib and mocetinostat. Both glesatinib and sitravatinib are orally bioavailable, spectrum-selective kinase inhibitors with distinct target profiles that are in development for the treatment of patients with NSCLC and other solid tumors. Glesatinib targets the MET receptor tyrosine kinase family and is in Phase 2 clinical development. Sitravatinib targets RET rearrangements, CHR4q12 amplifications (encompassing KDR, PDGFRA and KIT), and CBL and AXL mutations, and is in Phase 1b clinical development. Sitravatinib is also being evaluated in combination with nivolumab, a PD-1 inhibitor, for the treatment of patients with NSCLC. Sitravatinib is a potent inhibitor of the TAM (Tyro, Axl, Mer) and split (KDR, KIT) tyrosine kinase families, which regulate multiple stages in the cancer immunity cycle and are thought to enhance anti-tumor immunity by improving the efficacy of immune checkpoint inhibitors (anti PD-1/PD-L1). 

Our third product candidate is mocetinostat, an orally bioavailable, spectrum-selective Class 1 histone deacetylase inhibitor. Mocetinostat is in Phase 1b/2 clinical development in combination with durvalumab, MedImmune’s anti-PD-L1 immune checkpoint inhibitor, for the treatment of patients with NSCLC.  More information is available at www.mirati.com.

 

SOURCE Mirati Therapeutics, Inc.

Quality Control Inspector (Pharma/Medical Device) – Eastridge Workforce Solutions – San Diego, CA

February 13, 2017 – 12:53 pm

Experience in biotech, medical device, or pharmaceutical quality control is *required.*. Eastridge Workforce Solutions is searching for a qualified QC Inspector… $22 an hourFrom Indeed – Mon, 13 Feb 2017 20:53:57 GMT – View all San Diego jobs

Laboratory and Vivarium Assistant (La Jolla)

February 13, 2017 – 11:51 am

Laboratory and Vivarium Assistant
A local biotech company is looking for a part-time assistant / technician to be part of the in vivo neurobiology group and contribute to preclinical (nonclinical) research programs aimed at the development of diagno […

Social Media Sales Rep / Start February 27th – $50,000-$100,000/yr (San Diego)

February 13, 2017 – 11:25 am

17-year-old Digital Marketing company that provides Social Media, Web Marketing, SEO and other online marketing solutions to businesses throughout the USA. We love to hire recent college grads with a passion and a burning desire to jump-start their c […

Analytical Chemist

February 13, 2017 – 10:32 am

Eurofins Advantar Laboratories, Inc is searching for an Analytical Chemist in San Diego, CA.
Analytical Chemist responsibilities include, but are not limited to, the following :
? Develop, qualify and validate analytical test methods for drug produ […

Quality Assurance Assistant (Vista)

February 13, 2017 – 10:22 am

Quality Assurance Assistant
Duties and responsibilities:
? Generate and review manufacturing paperwork
? Inspect finished product, labels, and documentation before shipment
? Document Control: Assist in the review of all quality-related documents […

Production Chemist I-II (San Diego)

February 13, 2017 – 10:15 am

Candidate must have BS degree in Chemistry or related field to be considered. The person that is offered the position will be trained and responsible for following the peptide manufacturing process in a controlled cGMP environment, as well as perform […

Quality Assurance Technician (Vista)

February 13, 2017 – 10:01 am

Quality Assurance Technician
Duties and responsibilities:
? Floor inspections of all areas of manufacturing and production: Receiving, Warehouse, Weight room, Blend, Presses, Encapsulation, Polish, Sort, Coating, and Shipping
? Review manufacturin […

Research Associate II – Ajinomoto Althea, Inc. – San Diego, CA

February 13, 2017 – 9:58 am

Three to six (3-6) years of relevant experience in biotechnology. Is a fully integrated contract development and manufacturing organization providing clinical…From Ajinomoto Althea, Inc. – Mon, 13 Feb 2017 17:58:37 GMT – View all San Diego jobs